ArticleCancer medicine2023
Clinical impact of carbon-ion radiotherapy on hepatocellular carcinoma with Child-Pugh B cirrhosis.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Exploratory case series of conversion to carbon ion radiotherapy after systemic therapy in advanced hepatocellular carcinoma.International cancer conference journal · 2026Article
- Review
- Carbon-Ion Radiotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects: A Narrative Review.Journal of clinical medicine · 2025Review
- Treatment Outcomes in Patients Receiving Carbon-Ion Radiotherapy Versus Hepatectomy for Hepatocellular Carcinoma (≥4 cm): A Retrospective Study in Japan.Journal of clinical medicine · 2025Article
- Carbon-Ion Radiotherapy as a Local Treatment Option for Hepatocellular Carcinoma With Child-Pugh Class B Cirrhosis.Advances in radiation oncology · 2025Article
- Validation study on accuracy of our newly proposed methods for post-therapeutic liver reserve capacity estimation utilizingAnnals of nuclear medicine · 2025Article
- Prospective study of a rotating gantry with scanning beams of carbon-ion radiotherapy for choroidal malignant melanoma.Journal of radiation research · 2025Article
- Clinical indications and future directions of carbon-ion radiotherapy: a narrative review.Ewha medical journal · 2024Review
- Particle therapy in gastrointestinal cancer-a narrative review.Journal of gastrointestinal oncology · 2024Review
- Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma.Clinical and molecular hepatology · 2023Review
- Clinical impact of carbon-ion radiotherapy on hepatocellular carcinoma with Child-Pugh B cirrhosis.Cancer medicine · 2023Article
- Pencil Beam Scanning Carbon Ion Radiotherapy for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Article
- Treatment Planning Comparison of Gantry-based and Fixed Beams for the Treatment of Liver Tumors With Carbon Ion Therapy.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatocellular carcinoma (HCC) patients with Child-Pugh (CP)-B not eligible for surgery nor other focal therapy options due to impaired liver function, have very limited treatment options. This study aims to retrospectively investigate the toxicity and efficacy of Carbon-ion radiotherapy (C-ion RT) on HCC with CP-B patients. MATERIALS AND
methodsPatients with CP-B, no extrahepatic metastasis, and treated with C-ion RT between May 2000 and March 2020 were retrospectively extracted and included in this study.
resultsSixty-nine lesions of 58 patients were included. The median follow-up duration was 20.5 (2.7-108) months. During follow-up, recurrence was observed in 43 patients, including 2 local recurrences and 39 intrahepatic recurrences beyond the irradiation field. A grade 3 acute hepatotoxicity was observed in one patient during the observation period. No acute or late adverse event of grade ≥4 was observed. Overall survival was 80.4% and 46.0% at 1 and 2 years, respectively, and the median survival time was 22.6 months. Local control rate was 96.4% at both 1 and 2 years, and progression-free survival was 38.6% and 6.9% at 1 and 2 years, respectively, with a median of 9.7 months.
conclusionThe C-ion RT showed low toxicity and good local effect in patients with HCC and CP-B. Therefore, C-ion RT could be an appropriate treatment for patients with HCC with poor liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.